Is CEL-SCI Corporation (CVM) a Buy, Sell, or Hold?
AMEX : CVM
CEL-SCI Corporation — News
$1.335 USD
$0.09 (6.8%)
- Volume
- 102.54K
- Average Volume
- 527.05K
- Market Capitalization
- $9.17M
- P/E Ratio
- -0.38
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $13.48
- Year Low
- $0.89
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.60
| Source | Headline |
|---|---|
|
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data. businesswire.com - 2026-07-30 08:31:00 |
|
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer. businesswire.com - 2026-07-13 08:00:00 |
|
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care. businesswire.com - 2026-06-24 08:00:00 |
|
CEL-SCI Announces Closing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering. businesswire.com - 2026-06-16 16:01:00 |
|
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy. businesswire.com - 2026-06-16 08:00:00 |
|
CEL-SCI Corporation Announces Pricing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering. businesswire.com - 2026-06-14 19:03:00 |
|
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine. businesswire.com - 2026-06-12 08:00:00 |
|
CEL-SCI Reports Fiscal Second Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine. businesswire.com - 2026-05-18 08:00:00 |
|
CEL-SCI Announces Closing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering. businesswire.com - 2026-05-13 15:00:00 |
|
CEL-SCI Corporation Announces Pricing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering. businesswire.com - 2026-05-11 20:11:00 |
|
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia. businesswire.com - 2026-05-11 08:00:00 |
